Geron Corp (NASDAQ:GERN)

CAPS Rating: 3 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.

Recs

0
Player Avatar LouisAIrl (< 20) Submitted: 9/10/2012 11:55:00 AM : Outperform Start Price: $1.25 GERN Score: -26.64

Down too much today

Featured Broker Partners


Advertisement